Products
Cantourage developed a sourcing model in 2021 to allow global cannabis producers to supply Europe, now partnering with 65 growers across 15 countries.

Cantourage Group supplies pharmacies in Germany, UK and Europe with medical cannabis from licensed producers via EU-GMP manufacturing in Germany.
cantourage.comCrawled Nov 16, 2026
Cantourage developed a sourcing model in 2021 to allow global cannabis producers to supply Europe, now partnering with 65 growers across 15 countries.
Cantourage preserves and develops rare African cannabis strains through structured selection of unique phenotypes and genetics.
Cantourage combines indigenous knowledge with modern agriculture for sustainable, high-quality cannabis production.
Cantourage’s Fast Track Access platform lets nearly 40 cultivators from over 15 countries supply the European medical cannabis market.
Cantourage reported a record quarterly revenue of over EUR 25.6 million in Q1 2025.
Cantourage Group SE reported €51.4 million in revenue for 2024, exceeding its updated forecast of €46–50 million and growing 118% over 2023.
Cantourage Group SE recorded €24.9 million in revenue from January to August 2024, a 62% increase over the same period in 2023.
The supervisory board appointed Patrick Hoffmann as Philip Schetter’s interim successor on the Cantourage board until December 31, 2025.
Bophelo Bioscience & Wellness signed a processing and distribution agreement with Cantourage to access the European medical cannabis market.
Philip Schetter, Cantourage CEO, will speak at the Cannabis Europa 2021 conference in London.
Cantourage projected a high double-digit percentage increase in 2023 revenue compared to 2022 (EUR 14.1 million).
Cantourage recorded EUR 7.2 million in revenue in November 2024, a 30% increase from October’s previous high.
Patrick Hoffmann and Florian Holzapfel founded Pedanios GmbH, Germany’s first wholesale distributor for medical cannabis, when only about 200 patients had an exemption to access cannabis flowers.
Cantourage achieved break-even in 2023 and went public in autumn 2022 to support cannabis legalization in Germany.
Cantourage’s Fast Track Access platform helps global cultivators enter the European medical cannabis market while maintaining quality standards.
Cantourage GmbH is headquartered at Feurigstraße 54, 10827 Berlin, Germany.
Cantourage Group reports a Q3 EBITDA turnaround, achieving €1.9 million in profit compared to a €2.2 million loss in the prior period. The company’s EBITDA margin reaches 9.5%, signaling improved financial performance despite market price pressures. The expansion of its European operations appears to contribute to these gains.
Cantourage Group SE reports a €1.9 million EBITDA in Q3 2026, reversing a €2.2 million loss in the same period last year. Revenue slightly declines to €19.9 million from €20.3 million, while gross margin improves significantly to 35.3% from 18.1%. The company demonstrates strong operational efficiency gains despite a minor revenue drop.
Cantourage Group SE expands its **Telecan** platform to enhance digital healthcare access. The company integrates telemedicine solutions to improve remote patient consultations and medical services delivery. Telecan’s development aligns with Cantourage’s strategic focus on digital health innovation.
Cantourage Group SE finalizes the EU-GMP certification for Canadian cannabis processor **1530076 BC Ltd.**, marking its third such project. The company also secures a five-year exclusive deal for premium cannabis products from three unnamed producers.
Cantourage secures exclusive distribution rights for Green Karat’s EU and UK products after Green Karat achieves EU-GMP certification. The partnership expands Cantourage’s reach in regulated cannabis markets, leveraging Green Karat’s compliance with European manufacturing standards. Both companies strengthen their positions in high-quality, certified cannabis distribution across Europe.